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Background: Sickle cell disease (SCD) is a life-limiting inherited hemoglobinopathy that results in
significant complications and affects quality of life. Hematopoietic stem cell transplantation (HSCT)
is currently the only curative intervention for SCD; however, guidelines are needed to inform how to
apply HSCT in clinical practice.
Objective: These evidence-based guidelines of the American Society of Hematology (ASH) are intended
to support patients, clinicians, and health professionals in their decisions about HSCT for SCD.
Methods: The multidisciplinary guideline panel formed by ASH included 2 patient representatives and
was balanced to minimize potential bias from conflicts of interest. The Mayo Evidence-Based Practice
Research Program supported the guideline development process, including performing systematic evi-
dence reviews (through 2019). The panel prioritized clinical questions and outcomes according to their
importance for clinicians and patients. The panel used the Grading of Recommendations Assessment,
Development and Evaluation (GRADE) approach, including GRADE Evidence-to-Decision frameworks,
to assess evidence and make recommendations, which were subject to public comment.
Results: The panel agreed on 8 recommendations to help patients and providers assess how
individuals with SCD should consider the timing and type of HSCT.
Conclusions: The evidence review yielded no randomized controlled clinical trials for HSCT in SCD;
therefore, all recommendations are based on very low certainty in the evidence. Key recommendations
include considering HSCT for those with neurologic injury or recurrent acute chest syndrome at an early
age and to improve nonmyeloablative regimens. Future research should include the development of a
robust SCD registry to serve as a comparator for HSCT studies.
Summary of recommendations
Sickle cell disease (SCD) is the most common inherited clinically significant hemoglobinopathy in the United
States. Individuals with SCD are affected by multiple disease-related complications that result in significant
morbidities and early mortality. Hematopoietic stem cell transplantation (HSCT) is currently the only estab-
lished curative intervention for SCD that can restore normal hematopoiesis. The American Society of Hema-
tology (ASH) guideline panel addressed questions related to the use of HSCT for patients with SCD with
neurologic injury, frequent pain, or acute chest syndrome (ACS). The panel also addressed questions related
to the type of transplantation and donor used and age of the patient.
Submitted 28 January 2021; accepted 23 June 2021; final version published online 28
September 2021. DOI 10.1182/bloodadvances.2021004394.
The full-text version of this article contains a data supplement.
 2021 by The American Society of Hematology
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This guideline is based on updated and original systematic reviews of
evidence conducted under the direction of the Mayo Evidence-Based
Practice Research Program. The panel followed best practices for
guideline development recommended by the Institute of Medicine
and theGuidelines International Network.1-4 The panel used theGrad-
ing of Recommendations Assessment, Development and Evaluation
(GRADE) approach5-11 to assess the certainty of the evidence and
formulate recommendations.
Interpretation of strong and conditional
recommendations
The strength of a recommendation is expressed as either strong (“the
guideline panel recommends…”) or conditional (“the guideline panel
suggests…”) and has the following interpretation:
Strong recommendation
 For patients: Most individuals in this situation would want the rec-
ommendedcourseofaction, andonlyasmallproportionwouldnot.
 For clinicians: Most individuals should follow the recommended
course of action. Formal decision aids are not likely to be needed
tohelp individual patientsmakedecisionsconsistentwith their val-
ues and preferences.
 For policymakers: The recommendation can be adopted as policy in
most situations. Adherence to this recommendation according to the
guidelinecouldbeusedasaqualitycriterionorperformanceindicator.
 For researchers: The recommendation is supported by credible
research or other convincing judgments that make additional
research unlikely to alter the recommendation. On occasion, a
strong recommendation is based on low or very low certainty in
the evidence. In such instances, further research may provide
important information that alters the recommendations.
Conditional recommendation
 For patients: A majority of individuals in this situation would want
the suggested course of action, but many would not. Decision
aids may be useful in helping patients to make decisions consis-
tent with their individual risks, values, and preferences.
 For clinicians: Different choices will be appropriate for individual
patients, and clinicians must help each patient arrive at a manage-
mentdecisionconsistentwith thepatient’svaluesandpreferences.
Decision aids may be useful in helping individuals make decisions
consistent with their individual risks, values, and preferences.
 For policy makers: Policy making will require substantial debate
and involvement of various stakeholders. Performance measures
about the suggested course of action should focus on whether
an appropriate decision-making process is duly documented.
 For researchers: This recommendation is likely tobestrengthened
(for future updates or adaptation) by additional research. An eval-
uation of the conditions and criteria (and the related judgments,
research evidence, and additional considerations) that deter-
mined the conditional (rather than strong) recommendation will
help identify research gaps.
Interpretation of good practice statements
As described by the GRADE Guidance Group, good practice state-
ments endorse interventions or practices that the guideline panel
agreed have unequivocal net benefit yet may not be widely recognized
or used.12 Good practice statements in this guideline are not based
on a systematic review of available evidence. Nevertheless, they
may be interpreted as strong recommendations.
Values and preferences
The recommendations for HSCT in patients with SCD are presented
in terms of the primary SCD-related complications of concern, the age
of the patient, and the type of transplantation under discussion. The
importance of the patient’s and family’s preferences remained central
to the discussion and associated recommendations. These recom-
mendations, however, are generally based on low certainty in the evi-
dence. This dearth of data underscores the importance placed on
individualized patient care that involves shared decision making
between the provider and the patient and family. Furthermore, the bal-
ance of benefits and harms differs in children and adults when consid-
ering transplantation, both because of the increased risk of HSCT in
adults with SCD and potential gain in those with accumulated
SCD-related comorbidities. Therefore, it is particularly important to
adjust for patient and family preferences and to consider individual
patient/family values and risk threshold in the context of past experien-
ces with SCD.
Other evidence to inform decision criteria and
considerations
The panel recognizes that there may be significant uncertainty or var-
iability in how much people value the main outcomes of HSCT as a
result of insufficient knowledge regarding the risks and benefits of
myeloablative vs nonmyeloablative or reduced-intensity conditioning
(RIC) and alternative donor HSCT. In addition, there are no clear clas-
sification systems to determine if a patient with SCD has severe dis-
ease or if the patient will experience specific SCD complications in
their life course. Therefore, it can be difficult to accurately balance a
risk/benefit ratio of HSCT that takes into account an individual
patient’s lifetime experience. However, there is an assumption that liv-
ing without SCD is preferred over having unpredictable and debilitat-
ing complications that increase with age. In contrast, HSCT-specific
harms have been documented in several studies. These include
graft-versus-host disease (GVHD), infections, graft failure, infertility,
vital organ injury, and death. These transplantation-related risks are
detailed in themethodologic considerations below (Table 3). Because
these potential harms are not insignificant, they must be considered
along with the potential benefits that include a cure for SCD.
The panel was not able to assess how substantial the desirable antic-
ipated effects may be, because the extent and duration of benefit of
HSCT are not known as a result of incomplete long-term follow-up
data post-HSCT. Furthermore, the cost of transplantation compared
with that of standard of care is also not established. Although the
costs of HSCT are significant in the short term, they may be offset
by the reduced hospitalizations, decreased transfusions, and termina-
tion of costly SCD-specific medications that would no longer be
required when HSCT is successful. Additionally, the potential gains
from improved ability of affected individuals to attend school and
work could also help counterbalance the long-term costs of HSCT.
The feasibility of HSCT is also complicated because of concerns
with lack of trust on behalf of the patients, insufficient donor availability,
preexisting comorbidities, and poor access to care, including lack of
access to a transplantation facility. In more recent years, feasibility of
HSCT has substantially increased because of improvements in the
process of donor-recipient HLA match requirements and less toxic
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conditioning regimens that are more suitable for patients with preexist-
ing comorbidities.
Explanations and other considerations
These recommendations take into consideration resource use,
acceptability, feasibility, and effect on health equity. The ASH guide-
line panel acknowledged variability in patient and provider knowledge,
as well as variability in their perceptions of harms vs benefits and other
patient-important outcomes when developing these recommenda-
tions. Because of a lack of relevant data, the cost effectiveness of
most interventions could not be assessed.
Recommendations
Recommendation 1. The ASH guideline panel suggests HLA-
matched related HSCT rather than standard of care (hydroxyurea
(HU)/transfusion) in patients with SCD who have experienced an
overt stroke or have an abnormal transcranial Doppler ultrasound
(TCD) (conditional recommendation. very low certainty in the evidence
⨁).
Remarks:
 Consideration for transplantation should occur in all patients with
neurologic injury who have a matched related sibling donor.
 When considering transplantation for neurologic injury, children
younger than age 16 years who receive matched sibling donor
(MSD) HSCT have better outcomes than those older than age
16 years.
Recommendation 2. For patients with frequent pain, the ASH
guideline panel suggests using related matched allogeneic transplan-
tation rather than standard of care (conditional recommendation, very
low certainty in the evidence about effects ⨁).
Remark:
 Consideration for transplantation should be given to patients who
do not respond or have an inadequate response to standard of
care, such as HU, new targeted therapies, or chronic transfusion
therapies.
Recommendation 3. For patients with recurrent episodes of ACS,
the ASH guideline panel suggests using matched related allogeneic
transplantation over standard of care (conditional recommendation,
very low certainty in the evidence about effects ⨁).
Remark:
 Consideration for transplantation should be given to patients who
continue to have recurrent ACS despite optimal standard of care
(eg, HU, L-glutamine, crizanlizumab, and chronic transfusion
therapy).
Recommendation 4. For patients with SCD with an indication for
HSCT who lack an MSD, the ASH guideline panel suggests using
transplants from alternative donors in the context of a clinical trial (con-
ditional recommendation, very low certainty in the evidence about
effects ⨁).
Remark:
 Alternative donor transplantation has the potential to improve or
resolve disease manifestations in patients with severe SCD. The
risks related to transplantation complications should be balanced
with benefits derived from successful transplantation.
Recommendation 5. For allogeneic HSCT, the ASH guideline
panel suggests using either total-body irradiation (TBI) #400 cGy
or chemotherapy-based conditioning regimens (conditional recom-
mendation, very low certainty in the evidence about effects ⨁).
Recommendation 6a. For children with SCD who have an indica-
tion for allogeneic HSCT and an MSD, the ASH guideline panel sug-
gests using myeloablative conditioning over RIC that contains
melphalan/fludarabine regimens (conditional recommendation, very
low certainty in the evidence about effects ⨁).
Recommendation 6b. For adults with SCDwho have an indication
for allogeneic HSCT and an MSD, the ASH guideline panel suggests
nonmyeloablative conditioning over RIC that contains melphalan/flu-
darabine regimens (conditional recommendation, very low certainty
in the evidence about effects ⨁).
Recommendation 7. In patients with an indication eligible for
HSCT, the ASH guideline panel suggests using allogeneic transplan-
tation at an earlier age rather than an older age (conditional recom-
mendation, low certainty in the evidence about effects ⨁⨁).
Remarks:
 Recommendationscouldnotbemade if anMSDwasnot available
because of the paucity of available data.
 The impact of age on HSCT outcomemay also be affected by the
conditioning regimen used.
Recommendation 8. The ASH guideline panel suggests the use of
HLA-identical sibling cord blood when available (and associated with
an adequate cord blood cell dose and good viability) over bone mar-
row (BM) (conditional recommendation, very low certainty in the evi-
dence about effects ⨁).
Introduction
Aims of this guideline and specific objectives
The purpose of this guideline is to provide evidence-based rec-
ommendations for HSCT for SCD. The primary goals of this
guideline are to review and critically appraise the existing litera-
ture and provide recommendations for patients and health
care professionals to support their decision making. Through
improved provider and patient education using the available evi-
dence and evidence-based recommendations, this guideline
aims to provide clinical decision support for shared decision
making that will help identify which individuals with SCD should
be considered for HSCT.
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The target audience for this guideline includes patients, hematol-
ogists/HSCT providers, general practitioners, internists, other
clinicians, and decision makers. Policy makers interested in these
guidelines may include those involved in developing local,
national, or international plans with the goal of improving the
health of individuals with SCD. This document may also serve
as the basis for adaptation by local, regional, or national guideline
panels.
Description of the health problem
HSCT is a potential 1-time curative therapy for SCD. Although
considered acceptable therapy for many malignant and nonma-
lignant hematologic disorders, the use of HSCT in SCD contin-
ues to evolve, with new conditioning regimens, alternative
donors and methods of cell harvesting, and strategies for
GVHD prevention. Furthermore, as success rates after HSCT
are improving, so too are survival rates in children and adults
with SCD receiving disease-modifying medication and support-
ive therapy. Therefore, there are many questions regarding opti-
mal use of HSCT in SCD. The risk of harms associated with
HSCT must be considered when asking questions related to
the use of transplantation in SCD, especially when there are
approved targeted therapies (eg, HU, L-glutamine, voxelotor,
and crizanlizumab) and new potentially curative therapies under
development (eg, gene therapy). As a result, the panel focused
predominantly on (a) which individuals with SCD should be con-
sidered for HSCT based on specific SCD complications and
age, (b) what type of transplantation should be offered in terms
of conditioning (ie, myeloablative, nonmyeloablative, or reduced
intensity), and (c) what type of donor should be used (ie,
matched related donor, haploidentical related donor, or matched
unrelated donor [MUD]), including stem cell source (ie, marrow,
peripheral blood, or umbilical cord blood [UCB]). Final questions
evaluated by the panel had to have the potential for answers
within the available published data. Therefore, questions regard-
ing the safety and efficacy of gene-corrected autologous HSCT,
which are only now emerging, were not considered in these
guidelines.
The first allogeneic transplantation for SCDwas reported in 1984 in a
pediatric patient with SCD and acute myelogenous leukemia, who
was ultimately cured of both diseases.13 Since then,.1000 individu-
als with SCD have undergone HSCT, predominantly using HLA-
identical sibling donors, with .90% of all such patients cured of
SCD reported in the short-term follow-up.14 HSCT is an established
therapeutic option for patients with SCD with a clinical indication
and an HLA-identical sibling donor. Unfortunately, ,20% of patients
with SCD in the United States have anMSD, and a similar percentage
have an MUD in the registry,15,16 meaning that most patients who
might wish to pursue HSCTwill lack a well-matched donor. Alternative
donors, including unrelated, unrelated UCB, and haploidentical
related donors have improved access to HSCT. However, improved
options must balance the potentially increased risks associated with
these donor options.
This work represents the first attempt to develop guidelines for alloge-
neic HSCT in SCD based upon the available evidence. As the options
and outcomes improve for allogeneic HSCT in SCD, this guideline
may provide the basis for future periodic refinement.
The recommendations are presented according to the transplantation
indication based on SCD complication and then based on patient age
and type of transplantation under consideration. Throughout the rec-
ommendations, the panel notes the importance of the preferences
of the patients, their families, and their support structures in these
discussions.
There are no randomized clinical trials comparing HSCT and conser-
vative treatment of SCD; therefore, all the recommendations in this
guideline are supported by very low certainty in the evidence. Further-
more, the balance of benefits and harms of transplantation may be dif-
ferent in children and adults; therefore, decisions about when to use
transplantation must be individualized according to patient and family
values and preferences, especially values about the risk of harms.
How benefits and harms are balanced may also depend on setting
and access to standard treatments that may not be universally avail-
able (eg, in places where survival for children with SCD is not close
to 100%, such as inmiddle-income nations,17-19 transplantation could
be viewed more favorably as a treatment option). This guideline takes
the perspective of high-resourced settings.
Methods
The guideline panel developed and graded the recommendations and
assessed the certainty of the supporting evidence following the
GRADE approach.5-11 The overall guideline development process,
including funding of the work, panel formation, management of con-
flicts of interest, internal and external review, and organizational
approval, was guided by ASH policies and procedures derived from
the Guideline International Network (GIN)–McMaster Guideline
Development Checklist (http://cebgrade.mcmaster.ca/guidecheck.
html) and was intended to meet recommendations for trustworthy
guidelines by the Institute of Medicine and the GIN.1-4
Organization, panel composition, planning, and
coordination
The work of this panel was coordinated with 4 other guideline panels
(addressing other aspects of SCD) by ASH and the Mayo Evidence-
Based Practice Research Center (funded by ASH under a paid agree-
ment). Project oversight was provided by a coordination panel, which
reported to the ASH Guideline Oversight Subcommittee. ASH vetted
and appointed individuals to the guideline panel. TheMayoCenter vet-
ted and retained researchers to conduct systematic reviews of evi-
dence and coordinated the guideline development process,
including the use of the GRADE approach.8 The membership of the
panels and the Mayo Center team is described in Supplement 1.
The panel included hematologists, HSCT specialists, other physi-
cians, and patient stakeholders, including a recipient of a failed
HSCT and the mother of a patient who underwent a successful
HSCT, who all had clinical and research expertise on the guideline
topic; 1 co-chair was an HSCT expert, and the other co-chair was a
guideline development methodology expert.
In addition to synthesizing evidence systematically, the Mayo Center
supported the guideline development process, including determining
methods, preparing agendas and meeting materials, and facilitating
panel discussions. The panel’s work was performed using Web-
based tools (www.gradepro.org) and online and face-to-facemeetings.
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Guideline funding and management of conflicts
of interest
Development of these guidelines was wholly funded by ASH, a non-
profit medical specialty society that represents hematologists. Most
members of the guideline panel were members of ASH. ASH staff
supported panel appointments and coordinated meetings but had
no role in choosing the guideline questions or determining the
recommendations.
Members of the guideline panel received travel reimbursement for
attendance at in-person meetings, and the patient representatives
received honorariums of $100 per day for in-person meetings and
$25 per conference call. The panelists received no other payments.
Through the Mayo Clinic Evidence-Based Practice Research Pro-
gram, some researchers who contributed to the systematic evidence
reviews received salary or grant support. Other researchers partici-
pated to fulfill requirements of an academic degree or program.
Conflicts of interest of all participants weremanaged according to rec-
ommendations of the Institute of Medicine102 and the GIN.1 Partici-
pants disclosed all financial and nonfinancial interests relevant to
the guideline topic. ASH staff and the ASH Guideline Oversight Sub-
committee reviewed the disclosures and composed the guideline
panel to include a diversity of expertise and perspectives, including
individuals not expert or specialized in providing transplantation. On
appointment, no panelists were considered to have direct financial
conflicts with for-profit companies that could be directly affected by
the guideline. For example, companies that market chemotherapy
products used for conditioning prior to transplantation could be
affected by recommendations about the use of those products.
None of the Mayo-affiliated researchers who contributed to the sys-
tematic evidence reviews or who supported the guideline develop-
ment process had any such conflicts. A few panelists reported
financial relationships with for-profit companies that could be consid-
ered indirectly affected by the guidelines (eg, companies investigating
curative nontransplantation therapies such as gene therapies).
There was 1 deviation from usual ASH policy. When the panel was
formed, it was expected that recommendations about stem cell source
would be out of scope. Therefore, direct financial relationships with
companies that store and sell UCB and stem cells were not initially
considered a conflict of interest. However, recommendation 8 does
address stem cell source, (ie, favors cryopreserved cord blood over
BM). Because ASH staff did not note this, 2 panelists participated
in forming the recommendation despite their direct financial relation-
ships with cord blood banks. Under usual ASH policy, they should
have been recused from making judgments on or voting about individ-
ual domains (eg, magnitude of desirable consequences) or the direc-
tion or strength of the recommendation. After the recommendation
was formed, and during the approval of this guideline, members of
the Guideline Oversight Subcommittee agreed to allow this as a devi-
ation from usual policy.
Supplement 2 provides the complete disclosure of interests forms of
all panel members. In part A of the forms, individuals disclosed direct
financial interests for 2 years prior to appointment; in part B, indirect
financial interests; and in part C, not mainly financial interests. Part
D describes new interests disclosed by individuals after appointment.
Part E summarizes ASH decisions about which interests were judged
to be conflicts and how they were managed.
Supplement 3 provides the complete disclosure of interests forms of
researchers who contributed to these guidelines.
Formulating specific clinical questions and
determining outcomes of interest
The panel met in person and via conference calls to generate possible
questions to address. The panel then used an iterative process to pri-
oritize the questions described in Table 1.
The panel selected outcomes of interest for each question a priori
(Table 2), following the approach described in detail elsewhere.20
In brief, the panel first brainstormed all possible outcomes before rat-
ing their relative importance for decision making following the GRADE
approach.20
While acknowledging considerable variation in the impact on patient
outcomes, the panel considered the following outcomes as critical
for clinical decisionmaking across all questions. All questions identified
the same initial primary outcomes of interest, including disease-free
survival, overall survival (OS), acute and chronic GVHD, and graft fail-
ure/graft rejection. Additional primary outcomes of interest were based
on the question of interest for each question and were asked a priori.
Evidence review and development of
recommendations
For each guideline question, theMayo Center prepared aGRADEEvi-
dence-to-Decision (EtD) framework using the GRADEpro Guideline
Development Tool (www.gradepro.org).6-8 The EtD table summarized
the results of systematic reviews of the literature that were updated or
performed for this guideline. The EtD table addressed effects of inter-
ventions, resource use (cost effectiveness), values and preferences
(relative importance of outcomes), equity, acceptability, and feasibility.
The guideline panel reviewed draft EtD tables before, during, or after
the guideline panel meeting and made suggestions for corrections
and identified missing evidence. To ensure that recent studies were
not missed in addition to searches presented in supplement 4, panel
members were asked to suggest any studies that may have been
missed that fulfilled the inclusion criteria for the individual questions.
Table 1. Questions prioritized by the guideline panel
Prioritized questions
Q1: Should individuals with SCD and neurologic injury, including overt stroke, SCI, or
abnormal TCD, undergo MSD transplantation?
Q2: Should individuals with frequent pain requiring interventions by a health care
provider undergo MSD vs standard of care?
Q3: Should individuals with recurrent episodes of ACS undergo matched related
allogeneic transplantation vs standard of care?
Q4: Should individuals with SCD with an indication for HSCT (as above) who do not
have an MSD undergo nonmyeloablative transplantation from alternative donor vs
standard supportive care?
Q5: Should individuals with SCD undergoing allogeneic transplantation receive a TBI-
based regimen (low-dose TBI #400 cGy) or chemotherapy-based regimen?
Q6: Should individuals with SCD and an indication for HSCT (as above) and an MSD
receive myeloablative conditioning or RIC or nonmyeloablative conditioning?
Q7: Should age be a determining factor for HSCT with an MSD for individuals with
SCD with the above indication?
Q8: In pediatric patients with SCD, an indication for BM transplantation, and available
cryopreserved matched sibling UCB, should myeloablative BM transplantation be
used vs myeloablative UCB transplantation?
SCI, silent cerebral infarct.
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Under the direction of the Mayo Center, researchers followed the gen-
eral methods outlined in the Cochrane Handbook for Systematic
Reviews of Interventions (handbook.cochrane.org) for updating or
conducting new systematic reviews of intervention effects. When
existing reviews were used, judgments of the original authors about
risk of bias were either randomly checked for accuracy and accepted
or conducted de novo if they were not available or not reproducible.
For new reviews, risk of bias was assessed at the health outcome level
using the Cochrane Collaboration’s risk of bias tool for randomized
controlled trials (RCTs) or nonrandomized studies. In addition to con-
ducting systematic reviews of intervention effects, the researchers
searched for evidence related to baseline risks, values, preferences,
and costs and summarized findings within the EtD frameworks.6-8
Subsequently, the certainty of the body of evidence (also known as
quality of the evidence or confidence in the estimated effects) was
assessed for each effect estimate of the outcomes of interest follow-
ing the GRADE approach based on the following domains: risk of
bias, precision, consistency, directness of the evidence, risk of publi-
cation bias, presence of large effects, dose-response relationship, and
assessment of the effect of residual, opposing confounding. The cer-
tainty was categorized into 4 levels ranging from very low to high.9-11
Within this report, these categories are represented by the symbols,
as follows:
⨁⨁⨁⨁ High certainty in the evidence about effects
⨁⨁⨁ Moderate certainty in the evidence about effects
⨁⨁ Low certainty in the evidence about effects
⨁ Very low certainty in the evidence about effects
Interested readers may find more explanation about the GRADE
approach to assessing and rating certainty in a body of evidence in
other publications.21-27
During 2 separate 2-day in-person meetings, followed by online com-
munication and conference calls, the panel developed recommenda-
tions based on the evidence summarized in the EtD tables. For
each recommendation, the panel took a population perspective and
came to consensus on the following: the certainty in the evidence,
the balance of benefits and harms of the compared management
options, and the assumptions about the values and preferences asso-
ciated with the decision. The guideline panel also explicitly took into
account the extent of resource use associated with alternative man-
agement options. The panel agreed on the recommendations (includ-
ing direction and strength), remarks, and qualifications by consensus
or, in rare instances, by voting (an 80% majority was required for a
strong recommendation), based on the balance of all desirable and
undesirable consequences. The final guideline, including recommen-
dations, was reviewed and approved by all members of the panel.
The approach is described in detail in the accompanying article
describing the methods of development.28
Special methodologic considerations
1. A systematic review of HSCT in SCD was performed to assess
the effects of transplantation on outcomes of interest. Because of
variation in the components of standard of care, pooling of results
across studies of standard of care was not performed. Instead,
the panel identified published systematic reviews and key RCTs
Table 2. Outcomes prioritized by the guideline panel
Question Secondary outcome of interest
Q1: Should individuals with SCD and neurologic injury (overt stroke, SCI, or
abnormal TCD) undergo MSD transplantation?
1. Improvement/normalization of TCD velocity
2. Primary ischemic stroke
3. Secondary ischemic stroke
4. New or progressive SCI
5. New or progressive CNS vasculopathy
6. HRQOL
7. Engraftment kinetics
Q2: Should individuals with frequent pain requiring interventions by a health care
provider undergo MSD HSCT vs standard of care?
1. Change in frequency of acute pain episodes requiring acute care
2. Change in hospitalization frequency
3. HRQOL
4. Engraftment kinetics
Q3: Should individuals with recurrent episodes of ACS undergo MSD HSCT vs
standard of care?
1. Change in frequency of ACS
2. Change in hospitalization frequency
3. Resolution or improvement in chronic lung disease
4. HRQOL
5. Engraftment kinetics
Q4: Should individuals with SCD with an indication for HSCT (as above) who do
not have an MSD undergo nonmyeloablative transplantation from alternative
donor vs standard supportive care?
Same as Q1-3
Q5: Should individuals with SCD undergoing allogeneic transplantation receive a
TBI-based regimen (low-dose TBI#400 cGy) or chemotherapy-based regimen?
Same as Q1-3
Additional outcome: potential for fertility post-HSCT
Q6: What is the optimal conditioning regimen for individuals with SCD who have an
indication for HSCT and a matched sibling donor (myeloablative transplantation
vs reduced intensity or nonmyeloablative transplantation)?
Same as Q 1-3
Additional outcome: Potential for fertility post-HSCT
Q7: Should age be a determining factor for HSCT with MSD for individuals with
SCD with the above indication?
Same as above (Q6)
Q8: In pediatric patients with SCD undergoing matched related donor HSCT with
available cryopreserved matched sibling cord blood use the cord blood or BM as
donor source?
Same as above (Q6)
CNS, central nervous system; HRQOL, health-related quality of life.
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that separately evaluated various types of standards of care and
compared those with transplantation trials to derive its
recommendations.
2. Therewere insufficient numbers ofHSCTswith nonmatched sib-
ling donors (alternative donor transplantation) and high variability
in HSCT approaches in reports differing in types of nonmyeloa-
blative conditioning or RIC regimens in the literature to draw valid
conclusions. Therefore, the guideline development group collab-
oratedwith theCenter for Blood andMarrowTransplant Registry
(CIBMTR), aworking group of.300 transplantation centers that
contribute data on consecutive allogeneic and autologous trans-
plantations. Theaimwas todetermine the relativeeffects of donor
type (unrelated donor vs UCB vs haploidentical relative), HSC
source (peripheral blood vs BM), and transplantation condition-
ing intensity on outcomes in patients after HSCT with SCD.
The primary outcome of interest was event-free survival (EFS;
death from any cause or graft failure with or without recurrent
SCD as cause of treatment failure). Other outcomes studied
were OS (death from any cause) and acute and chronic GVHD
based on standard criteria. The methods and statistical analysis
have beenpreviously published.29 In brief, the analysis compared
the characteristics of patients by donor type or categorical varia-
bles and used a cumulative incidence estimator to assess the
probabilities of graft failure and acute and chronic GVHD com-
pared with other risks. Variables considered included age, sex,
performancescore, hematopoieticcell transplantationcomorbid-
ity index, recipientcytomegalovirusserostatus, donor type, condi-
tioning regimen intensity, graft type, and transplantation period.
Agewas treatedasabinary variable (#12vs13-49years). Impor-
tantly, the agecutoff at,13 yearswas determined statistically as
the optimal cut point in the Cox regression model for overall mor-
tality. Conclusions from this analysis were used in the develop-
ment of the guideline recommendations.
3. There is a clear difference between the recommendation of trans-
plantation for children living with SCD compared with that for
adults. Throughout the guideline process, the panel discussed
the differences in the potential benefits and harms between chil-
drenandadults.Thesedifferencesarereflected in thefinal recom-
mendations, where the population is clearly identified in the
recommendation (ie, “In children with SCD…” or “In adults
with SCD…”). In addition, these differences are reflected in
the distinction made regarding the strength of the recommenda-
tion and certainty in the evidence. Technical remarks also include
information pertinent to specific age groups.
4. The harms of HSCTwere evaluated generally with various condi-
tioning, donor types, and stem cell sources (Table 3). These
potential harms were considered in every recommendation
when balancing benefits and harms.
5. For all recommendations, in addition to health effects, the panel
also considered other important elements. These included feasi-
bility, resource requirements, and the impactonhealthcareequity
of transplantation in comparison with standard care. The panel
also considered how patients and families may value the adverse
healtheffectsof the interventions relative topotentialgains.These
are included for specific questions in the EtD criteria and
considerations.
Table 3. Potential harms (complications and adverse effects) of HSCT
Complication Description
Death Survival after HLA-identical sibling donor HSCT varies by age. In a large retrospective analysis of HSCT in patients with SCD, mortality occurred in 5%-20%
depending on age.14 The probabilities of OS and EFS are summarized below:
For patients ,16 y of age:
OS, 95%
EFS, 93%
For patients $16 y of age:
OS, 81%
EFS, 77%
In a more recent analysis of the data by CIBMTR, a higher incidence of mortality was observed in patients.13 y of age following myeloablative conditioning and
MSD HSCT.30
GVHD The development of GVHD after HSCT was a significant concern voiced by some patient representatives. The thought of dealing with a new chronic disease,
like chronic GVHD, might be perceived as worse than SCD for some patients, although it is possible that some may consider this an acceptable risk, depending
on severity, if balanced by cure from SCD. The incidence of GVHD after MSD HSCT and myeloablative conditioning is summarized below:
For patients #16 y of age:
acute GVHD (grade 2-4), 12.6%
chronic GVHD, 14.6%
For those .16 y of age:
acute GVHD (grade 2-4), 16%
chronic GVHD, 23%
Graft failure For some individuals considering HSCT, the biggest risk is that the procedure fails, and they have recurrent SCD. Graft failure is most often manifested as
autologous recovery and therefore recurrence of the SCD manifestations. Risk of graft failure varies by conditioning intensity, donor type, GVHD prophylaxis
(eg, use of T-cell depletion), and HLA match. After MSD HSCT, graft failure occurs in 5%-10% of patients.14
The risk of graft rejection increases as the conditioning regimen intensity decreases and if an alternative donor (HLA mismatched or unrelated) is used. Although
less frequent than GVHD, the risk of graft failure may carry a larger emotional burden than other HSCT complications and should be thoroughly discussed with
potential patients and families as well as familial donors if applicable.
Infection Infection is a common complication of SCT but is usually manageable. In many instances, infection may prolong hospitalization or cause additional
hospitalizations in individuals who have undergone SCT. In rare instances, infections might not respond to available treatment and could be fatal. The risk
decreases over time after SCT and as immune suppression is stopped. Infection is a common complication of GVHD.
Infertility Infertility risk after HSCT is an important consideration for all patients and in those with SCD. Infertility occurs frequently after myeloablative conditioning and is
nearly universal in postpubertal patients. However, with the advent of less intense conditioning, the risk of infertility is likely lower. The option of gamete retrieval
and cryopreservation is an increasingly considered option, although it is expensive and not universally available. This is an important consideration in patient
decision making
Malignancy The incidence of a therapy-related malignancy, particularly after myeloablative allogeneic HSCT, seems to be low overall.29 Risks after less intense conditioning
regimens are not known at this time. This risk should be discussed with potential patients and families.
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a. Feasibility. With respect to feasibility, the panel noted that
across settings, even in a high-resource country such as the
United States, HSCT may not be feasible. Within the United
States, feasibility varies by location, patient socioeconomic
status, or third-party payer. Feasibility is more substantially
problematic in resource-poor settings where the lack of
access to supportive care sufficient for transplantation pre-
cludes implementation. However, issues such as proximity
toa transplantationcenter,missedemployment, andpayment
are significant and may limit universal feasibility.31
b. Required resources.HSCT is a costly intervention. IfHSCT is
pursued during childhood, and it is assumed that the duration
forwhich thepatientwill be freeof thedisease is lifelong, there
will be large health care savings over the lifespan of the cured
individual. When undergoing transplantation as an adult,
therewill be lowerhealthcaresavings.Resourcesareneeded
for individuals undergoing transplantation and their support
systems regardlessofage that arenot alwaysornotoftencov-
ered by insurance and may limit feasibility for individuals.
c. Equity. Access to HSCT is not universal and often depends
upon socioeconomic status and adequate health care cover-
age. In addition, the transplantation center may be far away
from the patient’s home, necessitating additional financial
burdens in addition to separation from family and work.
d. Justification. The risk of adverse events (harms discussed
above) are balanced against benefits of not having SCD
and likelihood of increased survival.
How to use this guideline
ASH guidelines are primarily intended to help clinicians make deci-
sions about diagnostic and treatment alternatives. Other purposes
are to inform policy, education, and advocacy and to state future
research needs. They may also be used by patients. This guideline
is not intended to serve or be construed as a standard of care. Clini-
cians must make decisions on the basis of the clinical presentation of
each individual patient, ideally through a shared process that consid-
ers the patient’s values and preferences with respect to the antici-
pated outcomes of the chosen option. Decisions may be
constrained by the realities of a specific clinical setting and local
resources, including but not limited to institutional policies, time limita-
tions, or availability of treatments. This guideline may not include all
appropriate methods of care for the clinical scenarios described. As
science advances and new evidence becomes available, recommen-
dations may become outdated. Following this guideline cannot guar-
antee successful outcomes. ASH does not warrant or guarantee any
products described in this guideline.
Statements about the underlying values and preferences as well as
qualifying remarks accompanying each recommendation are its inte-
gral parts and serve to facilitate more accurate interpretation. They
should never be omitted when quoting or translating recommenda-
tions from this guideline. Implementation of the guideline will be facil-
itated by forthcoming decision aids.
Document review
Draft recommendations were reviewed by all members of the panel,
revised, and then made available online from 11 April 2019 until 13
May 2019 for external review by stakeholders, including allied organ-
izations, other medical professionals, patients, and the public. Nine
individuals and 2 organizations submitted comments. The document
was revised to address pertinent comments, but no changes were
made to recommendations. On 1 January 2021, the ASH Guideline
Oversight Subcommittee and the ASH Committee on Quality agreed
that the defined guideline development process was followed, and on
15 January 2021, the officers of the ASH Executive Committee
approved submission of the guideline for publication under the impri-




Should individuals with SCD and neurologic injury (overt stroke or
abnormal TCD) undergo MSD transplantation?
Recommendation 1
The ASH guideline panel suggests HLA-matched related
HSCT rather than standard of care (HU/transfusion) in
patients with SCD who have experienced an overt stroke or
have an abnormal TCD (conditional recommendation, very
low certainty in the evidence ⨁).
Remarks:
 Consideration for transplantation should occur in all
patients with neurologic injury who have a matched
related sibling donor.
 When considering transplantation for neurologic injury,
children younger than age 16 years who undergo MSD
HSCT have better outcomes than those older than age 16
years.
Specific background. Neurologic injury caused by overt stroke
and SCI is a major complication of SCD. Early large retrospective
observational studies demonstrated that for people with sickle cell
anemia (HbSS or HbSB0), up to 24% could be affected by stroke.32
These studies also showed that chronic red cell transfusion (CRCT)
and other supportive care therapy were useful in stroke prevention
but not curative.33 Furthermore, in the absence of chronic red blood
cell (RBC) transfusions, 67% of at-risk children will have a second
overt stroke.34 However, long-term CRCT is associated with risks
such as alloimmunization and transfusional iron overload. Therefore,
efforts to prevent primary or secondary stroke have focused on cura-
tive options such as HSCT.
Summary of the evidence. The panel reviewed outcomes related
to neurologic injury: abnormal cerebral blood flow as measured by
TCD, primary ischemic stroke, secondary ischemic stroke, and new
or progressive SCI. There were no RCTs comparing standard treat-
ment of primary or secondary stroke prevention and HSCT. Studies
reviewed included those SCD studies aimed at stroke prevention
and those HSCT studies that included neurologic outcomes in their
publications. A total of 31 studies were available for evaluation.
In summary, trials aimed at stroke prevention demonstrated that CRCT
can reduce the risk of first ischemic stroke in children with an abnor-
mal TCD. Children without significant CNS vasculopathy can be
safely transitioned from CRCT to HU.35 However, CRCT remains
the only option for disease stabilization in children with a previous
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ischemic stroke but is not always effective. Four trials15,36-38 con-
ducted from 1991 to 2011 included children who underwent
HSCT for prevention of primary or secondary stroke as their indication
for HSCT. The accumulated findings suggested stabilization of CNS
pathology on magnetic resonance imaging or a decrease in stroke
rate after HSCT compared with standard of care. Only 1 recent trial,
DREPAGREFFE, compared outcomes of HSCT with those of stan-
dard of care in children with SCDwho had an abnormal TCD.39 Over-
all, the HSCT group had more children who developed a normal TCD
compared with standard of care. In this study, new SCI was found in 3
children and cerebral arterial stenosis in 2 children receiving standard
care, whereas neither was observed after HSCT. There are no studies
that have been intentionally conducted in persons with SCD with SCI
alone (who did not have a history of overt stroke or abnormal TCD) to
evaluate the impact of HSCT on SCI alone.
Benefits. The panel agreed that HSCT has moderate anticipated
benefits for patients who have had a stroke or are at risk of having a
stroke, including protection from progressive neurovascular disease
without ongoing supportive care. The protective effect seems to be
equivalent, if not superior, to that observed with regular RBC transfu-
sions. Overall, the certainty of these estimated effects is very low,
because the only comparative trial relied upon a surrogate outcome
measurement (cerebral arterial velocity measured by TCD) of
stroke prevention.
Harms and burdens. There are several health-related risks associ-
ated with HSCT (Table 3). The evaluations of each potential harm
depend on the type of transplantation, the type of conditioning regi-
men/chemotherapy, and the age of the individual. These potential
harms and burdens are universally associated with HSCT but may
be of greater or lesser risk based on degree of SCD-related complica-
tions, age, or type of transplantation. The risk of graft failure/rejection
or GVHD is low to moderate in individuals who receive a matched
related donor transplant. Infection risk is higher with myeloablative
therapy.40 The guideline panel estimated the risk of death in MSD
HSCT to be small. The risk of infertility is high after myeloablative
HSCT. The risk of malignancy is low after myeloablative HSCT.
Rationale and key drivers for this recommendation. On the
basis of very low certainty in the evidence from noncomparative stud-
ies, the panel judged that the balance of benefits (cure and increased
survival) and harms (infertility, GVHD, and death) probably favors
HSCT for individuals with SCD with neurologic complications. How-
ever, given the available evidence, the guideline panel considered
the risk of adverse effects is probably small for most patients and their
providers.
EtD criteria and considerations. The panel noted that the most
common reason cited for a referral to HSCT for SCD is overt ischemic
stroke. In addition, patients and their families place a high importance
on stopping lifelong RBC transfusions. The panel agreed that there is
a potential for decreased interruption of work/school/activities if fre-
quent clinic or transfusion visits are not required. The panel also
agreed that there may be possibly important uncertainty or variability
in how much people value the main outcomes of preventing neuro-
logic complications, including understanding the risk of stroke/recur-
rent stroke and outcomes related to stroke, existing treatment
options, or the possibility of a cure. The panel realized there is
extensive variability in clinical practice and outcomes that may corre-
late with where individuals live and receive care.
The panel also agreed that there are marked differences in the recom-
mendation of HSCT for children comparedwith adults. The likely gains
for children are also greater than for adults, if HSCT is successful.
The complete EtD framework for this question, including evidence
tables, is available at https://guidelines.ash.gradepro.org/profile/
oLT2VwqQTbM.
Conclusions. The panel determined that there is low certainty in the
evidence that probably favors HSCT for patients with SCD and neu-
rologic complications. Despite limited comparative data, it is likely that
HSCT reduces the risk of new or recurrent ischemic stroke and SCI.
The panel identified the following additional research needs: (1)
research focused on patient values and preferences with regard to
neurologic outcomes, and (2) research focused on neurologic out-
comes and recovery after HSCT in those who had neurologic compli-
cations as an indication for HSCT.
Recommendation 2
Should individuals with frequent pain requiring interventions by a
health care provider undergo matched related allogeneic transplanta-
tion vs standard of care?
Recommendation 2
For patients with frequent pain, the ASH guideline panel sug-
gests using related matched allogeneic transplantation rather
than standard care (conditional recommendation, very low
certainty in the evidence about effects ⨁).
Remark:
 Consideration for transplantation should be given to
patients who fail to respond or have an inadequate
response to standard of care, such as hydroxyurea, new
targeted therapies or chronic transfusion therapies.
Specific background. Individuals with SCD experience frequent
and recurrent acute pain events that are the most common reason
for acute care use. In addition, patients with frequent pain events
requiring acute care use experience more morbidity and early mortality
than those with less frequent acute care use.41-43 Current treatments
for prevention of these painful events may include the use of HU,
CRCT, and oral L-glutamine or crizanlizumab, recently approved by
the US Food and Drug Administration. In addition, HSCT has been
used in patients with frequent painful events to prevent future epi-
sodes. The panel systematically reviewed the existing data and
appraised the evidence to determine how allogeneic transplantation
compares with the use of HU and CRCT to prevent recurrent acute
pain events in patients with SCD.
Summary of the evidence. Studies were examined for the primary
outcome of prevention of pain defined as $3 episodes of acute pain
requiring intervention by a health care provider. The studies were also
evaluated for the following additional outcomes: survival, engraftment,
and acute and chronic GVHD. Twenty-two studies were identified
from the literature in patients with SCD.15,37,38,44-62 In general,
sickle-related acute complications and RBC transfusions were
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stopped in patients who experienced stable donor engraftment. Sub-
sets of patients in each of the identified trials underwent HSCT
because of recurrent pain. A majority of these studies focused their
reporting on transplantation outcomes, and no studies compared
HSCT with standard of care for the outcome of prevention of pain.
When examining outcomes related to the prevention of pain post-
HSCT, acute painful episodes requiring hospitalization were largely
prevented when engraftment occurred. In addition, there was a lim-
ited amount of evidence that HSCT improved patient-reported out-
comes relevant to pain in small subsets of patients. Darbari et al44
described that patient-reported outcomes of pain intensity and
pain impact were significantly improved post-HSCT in a subset of
patients with only intermittent pain pre-HSCT. Saraf et al47 in
2016 reported significant improvement in patient-reported bodily
pain (measured by the SF36) 1 year post-HSCT. However, there
are reports of patients still experiencing pain post-HSCT. Forty per-
cent of patients post-HSCT had persistent pain requiring opioid
medications at 1 year post-HSCT, suggesting that HSCT may not
ameliorate chronic pain.44 Further study of chronic pain and the
impact of HSCT is needed, including longer-term follow-up post-
HSCT for patients with SCD.
The studies were case series or single-arm prospective cohort stud-
ies. The systematic review did not find any comparative RCTs of
patients with SCD. Because of this, using the GRADE process,
when considering the certainty in the evidence, certainty was consid-
ered to be very low to moderate.
Benefits, harms, and burdens. The potential benefit of matched
related allogeneic transplantation varies from small to moderate and
includes prevention of acute pain events. The overall incidence of
acute pain posttransplantation was found to be low to nonexistent.
However, the differentiation of the occurrence of acute vs chronic
pain events posttransplantation was difficult to ascertain from the pub-
lished evidence, given the lack of standard chronic pain definition and
lack of systematic reporting. In addition, the evidence for long-term
benefits of transplantation, such as prolonged survival (eg, survival
into adulthood for those undergoing transplantation in the pediatric
years) and improved HRQOL, compared with standard of care,
is lacking.
The risks of matched related allogeneic transplantation, including
GVHD, infection, graft rejection, and infertility, are discussed in detail
in recommendation 1. The additional risk of harm associated with this
particular recommendation is the potential for chronic pain that is not
entirely mitigated by HSCT.44 Certain pain-inducing complications of
SCD (eg, avascular necrosis) cannot be altered by transplantation.
Additionally, individuals with SCD may develop a secondary chronic
pain syndrome that is not directly improved by HSCT.44 Thus, while
acute pain events may be resolved, chronic pain may persist.
Rationale and key driver for recommendation. The balance
between benefits vs harms may or may not favor HSCT for patients
with SCDwho experience frequent acute pain events. The overall cer-
tainty in the evidence of effects is very low because of (1) the lack of
direct comparative RCTs of BM transplantation vs standard of care in
SCD, (2) the relatively short-term follow-up and small sample sizes of
the available studies, and (3) the lack of long-termwell-defined patient-
reported outcomes on pain after SCT.
Other EtD criteria and considerations. The benefit of preven-
tion of acute pain in patients with SCD who undergo HSCT was
felt to be a desirable effect that may balance the harms for
some patients.
The complete EtD framework for this question, including
evidence tables, is available at https://guidelines.ash.gradepro.org/
profile/pP1olBhxMyg.
Conclusions and research needs for this recommenda-
tion. The guideline panel determined there is overall very low certainty
in the evidence for a net health benefit with regard to outcomes impor-
tant to patients associated with HSCT in patients with SCD and fre-
quent acute pain events. Despite the absence of comparative data of
HSCT vs standard of care therapy in the prevention of acute pain in
patients with SCD, HSCT is suggested given the observational
data that demonstrate a strong effect on this outcome. The panel iden-
tified the following focus areas requiring research: (1) comparative
studies of HSCT vs standard of care (eg, RCTs) that include standard-
ized measures of pain pre- and posttransplantation, especially patient-
reported outcomes, to determine the impact of the intervention on
pain, (2) research to address the consequences of chronic opioid
therapy in patients with SCD and how this may affect the resolution
of pain post-HSCT, and (3) long-term follow-up studies of patients
who have undergone matched related allogeneic transplantation to
determine long-term benefits and risks related to this treatment. This
includes monitoring for late effects, stratified by type of transplantation
and age and including graft failure, organ function, and chronic pain.
Recommendation 3
Should matched related allogeneic transplantation vs standard of
care be used for patients with SCD with recurrent episodes of ACS?
Recommendation 3
For patients with recurrent episodes of ACS, the ASH guide-
line panel suggests using matched related allogeneic
transplantation over the standard of care (conditional recom-
mendation, very low certainty in the evidence about effects
⨁).
Remark:
 Consideration for transplantation should be given to
patients who continue to have recurrent ACS despite
optimal standard of care (eg, HU, L-glutamine, crizanlizu-
mab, and chronic transfusion therapy).
Specific background. Patients with SCD may experience recur-
rent episodes of ACS, which can be life threatening or fatal. ACS
or progressive chronic lung damage is a leading cause of mortality
in adults with SCD and poses a significant risk.63 Patients with fre-
quent ACS events also experience more morbidity. Current standard
treatment of ACS prevention may include HU, CRCT, and oral
L-glutamine, recently approved by the US Food and Drug Administra-
tion. In addition, HSCT has been performed in patients with ACS
events to prevent recurrent episodes. The panel systematically
reviewed the existing data for comparison of HSCT and standard
treatment and appraised the evidence to determine how HSCT for
SCD compares with HU and CRCT to prevent recurrent ACS events.
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Summary of the evidence. Studies were examined for the primary
outcome of ACS prevention and were selected if the indication for
HSCT was explicitly stated as ACS events (recurrent or not).
The studies were also evaluated for the following 3 additional out-
comes: survival, engraftment, and acute and chronic GVHD. Sixteen
studies were identified from the literature in patients with
SCD.15,38,45,47-49,51-53,56-58,60,64,65 Collectively, these studies dem-
onstrate that ACS events no longer occurred in those cases where
the HSCT procedure was successful. Additionally, some studies mon-
itored lung function with pulmonary function tests post-HSCT. No
worsening of pulmonary function was noted in these patients moni-
tored post-HSCT; however, the follow-up period of most studies
was limited (,5 years in most cases). Comparatively, the recurrence
of ACS events was not eliminated with standard of care treatments,
such as HU and CRCT. For patients treated with HU and CRCT,
the reduction in ACS event recurrence varied from 71% to
92%.66,67 Additionally, in a randomized phase 3 trial of the new
L-glutamine agent, reduction in ACS was seen in 63% of patients
relative to those who received placebo.68
The HSCT studies reviewed were case series or single-arm prospec-
tive cohort studies. The systematic review did not find any comparative
RCTs of HSCT vs standard of care therapies of patients with SCD.
Because of this, using theGRADE process when considering the cer-
tainty in the evidence, certainty in the studies was considered to be
very low to intermediate.
Benefits. The potential benefit of matched related HSCT was
judged to be moderate and includes prevention of recurrent ACS
events and stabilized pulmonary function test results.69 The overall
incidence of ACS post-HSCT was negligible or nonexistent after suc-
cessful HSCT. However, the evidence for long-term benefits of
HSCT, such as prolonged survival (eg, survival into adulthood for
those undergoing transplantation as children), reduction of long-
term chronic lung disease (eg, restrictive lung disease), and improved
HRQOL compared with standard of care is lacking.
Harms. The harms of matched related allogeneic transplantation have
been discussed in detail in recommendation 1. The potential for harm
specific to this question is the inability to reverse some elements of
chronic lung disease, such as restrictive lung disease. There are no spe-
cific associated harms thought to be relevant to this recommendation.
Rationale and key driver for recommendation. The balance
between benefits vs harms may favor HSCT for patients with SCD
who experience frequent or severe ACS events. The overall certainty
in the evidence of effects is very low because of the lack of direct com-
parative studies and insufficient data on prolonged survival or reduc-
tion of preexisting or new-onset chronic lung disease for those who
have undergone HSCT. However, the panel recognized that long-
term survival outcomes are not improving in adults with SCD who
receive standard of care therapy, and among adults, chronic pulmo-
nary disease is prevalent and progressive and leads to higher mortality
risk. In addition, transplantation-related harms are known to be worse
in adults compared with children. The benefit of prevention of ACS in
patients with SCD after successful HSCT was judged a desirable
effect that may balance the harms in selected high-risk patients.
Other EtD criteria and considerations. In addition, the panel
acknowledged there is no uncertainty in the benefit of prevention of
ACS and that standard of care therapies such as HU can be very
effective at prevention of ACS events for some patients. Decisions
regarding patients’ treatment preferences were acknowledged to be
varied, where some patients may be ready to take any risk for the ben-
efits of therapy, while others may not.
The complete EtD framework for this question, including evidence
tables, is available at https://guidelines.ash.gradepro.org/profile/
GEEaIX1nF1I.
Conclusions and research needs for this recommenda-
tion. The guideline panel determined there is overall low certainty
in the evidence for a net health benefit in outcomes important to
patients associated with BM transplantation in patients with SCD
and frequent or severe ACS events. Despite the absence of compar-
ative data of HSCT vs standard of care therapy in the prevention of
ACS events in SCD, HSCT is justified in light of the observational
data that demonstrate a strong effect on this outcome (ie, eliminates
ACS after successful HSCT). The panel identified the following
focus areas in need of research: (1) comparative prospective studies
of HSCT compared with standard of care (eg, studies that include
standardized measures of pulmonary complications pre- and post-
transplantation, with a focus on patient-reported outcomes [eg,
HRQOL and other functional outcomes], pulmonary function, and
exercise capacity testing to determine the impact of the intervention
on lung function), (2) research to address the pulmonary complica-
tions that would justify HSCT in patients with SCD, and (3) long-
term follow-up studies in patients after matched related HSCT to
determine long-term benefits and risks related to this treatment.
This research includes monitoring for late effects stratified by type
of transplantation and age and for graft failure and organ function.
Recommendation 4
Should individuals with SCD with an indication for SCT (as above)
who do not have an MSD undergo nonmyeloablative transplantation
from alternative donor vs standard supportive care?
Recommendation 4
For patients with SCD with an indication for HSCT who lack an
MSD, the ASH guideline panel suggests using transplantation
from alternative donors in the context of a clinical trial (condi-
tional recommendation, very low certainty in the evidence about
effects ⨁).
Remark:
 Alternative donor transplantation has the potential to improve or
resolve disease manifestations in patients with severe SCD. The
risks related to transplantation complications should be balanced
with benefits derived from a successful transplantation.
Specific background. Fewer than 20% of individuals with SCD
have an HLA-matched sibling donor.70 This observation has prompted
alternative donor studies including HSCT with MUDs and haploident-
ical familial donors, often with reduced-intensity and nonmyeloablative
regimens designed to achieve engraftment while reducing toxicity and
late effects. For all these efforts, outcomes of prime importance
include successful donor engraftment, low transplantation-related
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complications such as GVHD and organ toxicity, successful immune
reconstitution, and low mortality.
Summary of the evidence. Studies were examined for the primary
outcomes of survival, graft failure/rejection, and acute and chronic
GVHD as well as secondary outcomes of interest from recommenda-
tions 1 to 3 where appropriate. Alternative donor stem cell sources
include MUD marrow, cryopreserved unrelated UCB products, and
haploidentical familial donor stem cells. Because of the rather recent
development of clinical trials of alternative donor HSCT for SCD, the
number of transplantations reported for each stem cell source is small.
The systematic review summarized 17 small studies45,52,53,71-84 to
evaluate unrelated donor (marrow) HSCT, unrelated donor (cord)
HSCT, and haploidentical familial donor HSCT. All of the initial alterna-
tive donor studies were discouraging, with a high incidence of graft
rejection (in the unrelated UCB and most haploidentical trials) or
GVHD (in the MUD and 1 pediatric haploidentical trial). More recently
however, results have been much more encouraging, with decreased
graft rejection and GVHD and improved survival. Since 2017, OS has
been 79% to 100% and EFS 50% to 91% following alternative donor
HSCT for SCD.29,45,52,53,71-85 Details regarding organ toxicity and
immune reconstitution are sparse. Results suggest these alternative
donor options are increasingly successful.
Benefits. The number of patients receiving transplants from alterna-
tive donors is small and includes mostly children and young adults.
The primary benefit is the ability to treat individuals with SCD with
HSCT even if an MSD is not available. Early short-term follow-up after
successful HSCT with alternate donors has demonstrated donor-
derived hematopoiesis, correction of hemoglobin levels, successful
cessation of chronic transfusion therapy averting an increasing iron
load, control of pain episodes resulting in improved HRQOL, stabiliza-
tion of CNS changes related to vasculopathy as demonstrated by
cerebral imaging, and maintenance of IQ without the anticipated dete-
rioration over time. The early benefits described above as well as long-
term effects on other organ systems such as the lungs, kidneys, and
gonads must be carefully tracked over time to define pros and cons
for patients after successful alternative donor HSCT and to determine
whether they align with benefits already established for MSD HSCT.
Harms. The toxicity burdens associated with alternative donor HSCT
must be balanced with benefits in relation to mitigating the symptoms
of SCD. The treatment-related toxicities that occur at high rates with
alternative donor HSCT include graft rejection (in the unrelated UCB
and early haploidentical trials) or GVHD (in the MUD and 1 pediatric
haploidentical trial). Data on immune reconstitution and susceptibility
to infection as well as regimen-related organ toxicity have not been
well documented. Mortality has been higher than with MSD HSCT
when considering all alternative donor HSCTs together; however,
more recent results have beenmuchmore encouraging, with decreased
graft rejection andGVHD and improved survival, especially in the haploi-
dentical setting. However, because alternative donorHSCTwas initiated
more recently, less is known about potential harms and late complica-
tions because of the smaller number of patients undergoing transplanta-
tion and shorter duration of follow-up (as compared with MSD HSCT).
Rationale and key drivers for recommendation. The balance
between benefits vs harms may favor HSCT with alternative donors
for patients with severe SCD only within the context of a clinical trial.
The overall certainty in the evidence of effects is very low because of
the lack of current available data and long-term follow-up. However, the
panel recognized that the benefits associated with a potential cure,
which include potentially slowing or even improving the organ dysfunc-
tion that occurs as patients with SCD age and improving HRQOL, may
outweigh concerns about increased risks associated with alternative
donor HSCT, particularly in the context of clinical trials where eligibility
criteria are selected to restrict this intervention to patients with severe
SCD and ensure detailed posttransplantation monitoring.
Other EtD criteria and considerations. The panel agreed that
after alternative donor HSCT, there is a potential for decreased inter-
ruption of work/school/activities if patients remain transfusion and
hospitalization independent and organ function is stabilized. The eligi-
bility criteria for alternative donor HSCT studies may bemore stringent
because of the potential for increased risk. Furthermore, the nonmye-
loablative conditioning or RIC commonly used in the alternative donor
setting may allow consideration of HSCT in patients with more severe
disease manifestations and end organ damage. The panel recognized
that this is a group of patients likely to have increased health care use
and poor QOL (because of SCD) and may benefit more from suc-
cessful HSCT than less severely affected individuals. The panel
agreed that there may be important uncertainty or variability in how
much patients and families value a cure in the context of increased
potential risks and fear of the unknown as compared with standard
treatment measures. The panel found significant variability in accep-
tance based on the patient’s social situation and physician practice.
The panel also agreed that there are significant differences in the rec-
ommendation of HSCT for children, adolescents, and adults because
of inherent risks from HSCT associated with patient age, disease sta-
tus, and expected longevity.
The complete EtD framework for this question, including evidence
tables, is available at https://gdt.gradepro.org/app/handbook/
handbook.html.
Conclusions and research needs for this recommenda-
tion. The guideline panel concluded that there is very low certainty
regarding nonmyeloablative or reduced-intensity alternative donor
HSCT for patients with SCD. All reports are short-term descriptions
and have variable outcomes. As was observed in the MSDHSCT set-
ting, most studies with alternative donors report only on transplanta-
tion outcomes such as survival, engraftment, and GVHD, but not on
disease-specific outcomes. Additional studies must assess long-
term effects of HSCT on disease-specific outcomes with regard to
age, stem cell source, transplantation approach, degree of HLA
matching, stability of donor cell engraftment and level of chimerism,
and degree of organ stabilization or improvement.
Recommendation 5
Should allogeneic transplantation with TBI-based regimens (low-
dose TBI #400 cGy) vs chemotherapy-based regimens be used
for patients undergoing allogeneic transplantation for SCD?
Recommendation 5
For allogeneic HSCT, ASH guideline panel suggests using
either TBI #400 cGy or chemotherapy-based conditioning
regimens (conditional recommendation, very low certainty in
the evidence about effects ⨁).
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Specific background. Chemotherapy-based conditioning with
busulfan and cyclophosphamide, with or without serotherapy with
antithymocyte globulin, represents the standard of care for pediatric
patients with SCD undergoing MSD HSCT. Although highly effective
in children, this regimen limits access for a large fraction of adults with
severe disease and other comorbidities given the greater potential for
toxicity in the population of adults with SCD. As the management of
pediatric patients has improved, many are delaying the decision
regarding HSCT until adulthood, when the disease burden increases.
To address this in the adult population, nonmyeloablative regimens
based on low-dose TBI have been developed and seem highly effec-
tive in reversing the disease. However, the long-term effects of irradi-
ation remain a concern, and there have been no direct comparisons of
these conditioning regimens in a prospective randomized trial.
Summary of the evidence. Studies were examined for the primary
outcomes of survival, graft failure/rejection, and acute and chronic
GVHD; secondary outcomes of interest from recommendations 1 to
3 where appropriate; and risk for malignancy and potential for fertility
post-HSCT. No studies were identified that directly addressed the
long-term effects of low-dose TBI in the setting of allogeneic HSCT
for SCD. In 1 report,86 there were no late malignancies described
among 30 patients with SCD conditioned with low-dose TBI; how-
ever, the follow-up was brief. Additionally, there were case reports
describing malignancies (eg, myelodysplastic syndrome and acute
leukemia) in patients with SCD after undergoing allogeneic transplan-
tation with chemotherapy-based regimens87 and low-dose TBI-based
regimens88,89 and in the absence of transplantation,87,90 making attri-
bution difficult. Only 1 report described the assessment of fertility after
low-dose TBI in 31 patients and noted no effect on the hypothalamus-
pituitary-adrenal axis and no effect on male gonadal function (male
participants underwent testicular shielding). Female participants had
evidence of SCD-related reduced ovarian function before transplanta-
tion, which worsened with transplantation. Three natural pregnancies
were described in 2 women, demonstrating fertility preservation is
possible after low-dose TBI.
Benefits, harms, and burdens. The major benefit of low-dose
TBI-based conditioning is the potential for fertility preservation, which
was viewed by the panel as significant. However, this was based on 1
published report with a limited sample size. Although not definitive,
there is a concern that fertility-sparing regimens based upon low-
dose TBI may be associated with a risk of myelodysplastic syndro-
me/acute leukemia that is higher than that associated with regimens
based upon myeloablative chemotherapy. As such, the benefit of fer-
tility preservationmay comewith an increased risk of this complication.
However, the limited data currently in the literature are insufficient to
assess the potential benefits and burdens of the 2 approaches with
respect to the outcomes.
Rationale and key drivers for this recommendation. The bal-
ance of benefits vs harms favors neither low-dose TBI nor
chemotherapy-based conditioning regimens for patients undergoing
allogeneic transplantation for SCD. There were no specific studies
found to address the concerns of long-term effects of low-dose irradi-
ation in the context of allogeneic transplantation. However, we identi-
fied case reports of myelodysplastic syndrome/acute leukemia in
patients with SCD after both chemotherapy-based and low-dose
TBI-based regimens along with reports of an increased incidence of
myelodysplastic syndrome/acute leukemia in patients with SCD
who had not undergone transplantation, demonstrating the need for
long-term follow-up studies. We identified a report of preservation of
fertility with the low-dose TBI approach.
Other EtD criteria and considerations. The panel noted that
the improved management of children with SCD has shifted the con-
sideration of HSCT for many into adulthood. The anticipated toxicity of
myeloablative conditioning in adults with accumulating organ damage
has prompted the development of nonmyeloablative transplantation
with low-dose TBI to enable HSCT in this population. Patients and
their families place a high value on the option for curative therapy in
adults afforded by this approach. Patients and their families also place
a high value on reproductive fitness, and the infertility associated with
myeloablative conditioning is a concern that has historically limited the
acceptance of myeloablative conditioning and transplantation in SCD.
The panel also agreed that there may be possibly important uncertainty
or variability in how much people value the outcome of a successful
HSCT when compared with the limited long-term data on the possible
risks of TBI compared with chemotherapy-based conditioning.
The complete EtD framework for this question, including evidence
tables, is available at https://guidelines.ash.gradepro.org/profile/
JV5JRlUUhfs.
Conclusions and research needs for this recommenda-
tion. The guidelines panel made a conditional recommendation
based on very low certainty because of the absence of sufficient/
good/valid data in the literature. Further research is warranted, includ-
ing registry analyses that are conducted at long-term follow-up com-
paring outcomes based upon transplantation conditioning.
Furthermore, fertility in SCD has not been well studied outside of
the field of transplantation, and efforts to characterize the effects of
SCD on fertility are warranted. Detailed assessments of fertility prior
to transplantation and during extended follow-up are also warranted.
This will allow patients to make better-informed decisions on whether
to pursue transplantation and, if differences between regimens are
established, choose a regimen that reflects the proper balance of
competing benefits and burdens.
Recommendation 6
Should individuals with SCD and an indication for HSCT (as above)
and an MSD receive myeloablative conditioning, RIC, or nonmyeloa-
blative conditioning?
Recommendation 6a
For children with SCD who have an indication for allogeneic
HSCT and an MSD, the ASH guideline panel suggests using
myeloablative conditioning over RIC that contains melphalan/
fludarabine regimens (conditional recommendation, very low
certainty in the evidence about effects ⨁).
Recommendation 6b
For adults with SCD who have an indication for allogeneic
HSCT and an MSD, the ASH guideline panel suggests non-
myeloablative conditioning over RIC that contains melpha-
lan/fludarabine regimens (conditional recommendation, very
low certainty in the evidence about effects ⨁).
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Specific background. Although HSCT has curative potential in
SCD, outcomes for the subgroup of children younger than 16 years
of age undergoing MSD HSCT are better compared with those for
adults. Adults with SCD are more likely to have accumulated
disease-related morbidities, which may limit their ability to participate
in HSCT. To optimize outcomes in both children and adults, alternative
conditioning regimens that include reduced-intensity or nonmyeloabla-
tive approaches must be explored. Unfortunately, there have been no
direct comparisons of these conditioning regimens in a prospective
randomized trial controlling for type of donor and indication for trans-
plantation. Therefore, there is very low certainty in the evidence sup-
porting the recommendations that follow.
Summary of the evidence. Studies were examined for the primary
outcomes of survival, graft failure/rejection, and acute and chronic
GVHD; secondary outcomes of interest from recommendations 1 to
3 when appropriate; and potential for fertility post-HSCT. The panel
was unable to find any study that directly compared outcomes in chil-
dren or adults undergoing HSCT using myeloablative vs either RIC or
nonmyeloablative conditioning. However, the committee evaluated
data from the CIBMTR and addressed the comparison of interest
among common conditioning regimens administered in HSCT.29
This registry data included a cohort of 910 patients who underwent
HSCT byMSD, unrelated donor, andHLA-haploidentical family donor.
Myeloablative conditioning was busulfan based, and nonmyeloablative
conditioning consisted of low-dose TBI with in vivo T-cell depletion.
RIC regimens, analyzed as a single group, consisted almost entirely
of a combination of melphalan/fludarabine with or without thiotepa.
The predominant conditioning regimen was myeloablative in 348
(62%) of 558 transplantions with an HLA-matched sibling donor.
EFS was superior in those younger than 13 years of age. There
was no significant difference in EFS between recipients of transplants
from nonsibling donors. Conditioning regimen intensity was not asso-
ciated with survival after HLA-identical sibling HSCT. However, graft
failure was higher after RIC compared with myeloablative (hazard ratio
[HR], 0.28; 95% confidence interval [CI], 0.13-0.57; P, .0001) and
nonmyeloablative (HR, 0.29; 95% CI, 0.08-1.00; P5 .049) regimens.
EFS also was lower after RIC compared with myeloablative (HR, 0.38;
95% CI, 0.21-0.67; P5 .00080) and nonmyeloablative (HR, 0.36;
95% CI, 0.13-0.94; P5 .036) regimens. The rate of chronic GVHD
was highest in patients treated with myeloablative regimens, less
high in those receiving RIC regimens, and lowest in those receiving
nonmyeloablative conditioning regimens. When OS is compared
across all regimens (myeloablative, reduced intensity, and nonmyeloa-
blative), nonmyeloablative conditioning has the highest survival advan-
tage a large part because of the lower rate of chronic GVHD.
Therefore, a nonmyeloablative regimen is recommended over RIC in
older patients, because the HR for EFS was significantly higher
(1.00 vs 1.97; 95% CI, 1.15-3.36; P5 .013).
Benefits. Potential benefits associated with a nonmyeloablative pre-
parative regimen include a reduced risk of mortality and GVHD in
adults after HSCT, although EFS does not seem to be different after
myeloablative and nonmyeloablative regimens.
Harms. Potential harms of myeloablative conditioning, including risk
of infection and infertility (Table 3), were previously discussed. Addi-
tional potential harms associated with RIC regimens that rely upon a
combination of melphalan/fludarabine include inferior EFS. Another
potential harm is the increased risk of graft failure associated with
RIC regimens. Therefore, regimens using RIC must be individually
evaluated for outcomes and risks to provide better comparisons of
myeloablative and nonmyeloablative regimens.
Rationale and key driver for recommendation. The guideline
panel determined that there is very low certainty in the evidence for a
net health benefit vs harm from using a nonmyeloablative or reduced-
intensity regimen over a myeloablative regimen. The strength of the
recommendations is weakened by the retrospective nature of the
studies examined for comparison of outcomes. In addition, the deci-
sion to pursue HSCT, the timing of HSCT, the choice of conditioning
regimen intensity, and the choice of an optimal alternative donor when
there is no sibling donor were not controlled for or considered in these
comparisons.
Other EtD criteria and considerations. The panel considered
the potential for improved survival in adults receiving a less intensive
chemotherapy regimen. The panel acknowledged that the availability
of TBI may depend on treatment center and geographic location. The
panel also acknowledged that myeloablative regimens may result in
higher transfusion requirements and other supportive care measures.
The complete EtD framework for this question, including evidence
tables, is available at https://guidelines.ash.gradepro.org/profile/
WISE0dFCFEM.
Conclusions and research needs for this recommenda-
tion. The panel concluded there is very low certainty in the evidence
supporting these recommendations. The panel identified extensive
additional research needs for these recommendations. Additional
follow-up and investigation of the risk of treatment-related malignan-
cies after nonmyeloablative conditioning regimens should be pursued.
These data should be systematically analyzed. It is also recommended
by the panel that conditioning regimens for HSCT for SCD should be
compared in prospective clinical trials.
Recommendation 7
Should age be a determining factor for HSCT with MSD for individ-
uals with SCD with the above indication?
Recommendation 7
In patients with an indication eligible for HSCT, the ASH
guideline panel suggests using allogeneic transplantation
at an earlier age rather than an older age (conditional re-
commendation, low certainty in the evidence about effects
⨁⨁).
Remarks:
 Recommendations could not be made if an MSD was not available
because of the paucity of available data.
 The impact of age on HSCT outcome also may be affected by the
conditioning regimen used.
Specific background. It is well documented that SCD complica-
tions accrue with age. Certain complications resulting in tissue death
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such as avascular necrosis and ischemic stroke cannot be reversed
by HSCT. Therefore, it is necessary to assess if individuals with
SCD should undergo HSCT at an earlier age or if the benefits of
HSCT will still be valuable at later ages.
Summary of the evidence. Studies were examined for the primary
outcomes of survival, graft failure/rejection, and acute and chronic
GVHD as well as secondary outcomes of interest from recommenda-
tions 1 to 3 where appropriate. Given the absence of studies that
directly compared outcomes in younger vs older patients with SCD
undergoing HSCT using an MSD, the panel examined data from
CIBMTR. In that study, EFS was highest in children younger than
age 13 years and with an MSD.29 Patients older than age 13 years
had not only lower EFS (HR, 1.74; P5 .0014) but also lower OS
(HR, 3.15; P , .0001) and higher chronic GVHD risk (HR, 1.46;
P5 .019). However, the impact of age on outcomes is also depen-
dent on the type of HSCT. With myeloablative conditioning, the risk
of chronic GVHD is significantly higher in those older than 15 years
of age. In contrast, these findings may be mitigated with nonmyeloa-
blative conditioning.91 Several recent studies of HSCT in adults using
nonmyeloablative conditioning demonstrated no chronic GVHD or
associated transplantation-related mortality. EFS was only 87%,
because 13% had graft rejection.46,82,86
Benefits. The anticipated benefits of transplantation at a younger
age could be large and include lower GVHD risk and decreased
transplantation-related mortality as well as improved EFS with less
graft rejection. Additional benefits might include the preservation of
organ function as a result of HSCT being performed before there
were substantial SCD-related organ complications.
Harms of HSCT include risk of infection, GVHD, graft rejection, risk of
secondary malignancy, and infertility. However, these harms affect
individuals with SCDof all ages undergoingHSCT. No current studies
have found additional harms secondary to performing HSCT in youn-
ger individuals with SCD. The harms related to HSCT continue to
depend mostly on the type of transplantation conditioning used.
Rationale and key driver for recommendation. The balance
between benefits vs harms in early transplantation probably favors
transplantation at a younger vs older age but may be influenced by
the presence of an MSD and the severity of the disease. However,
the overall certainty of effects is low given the lack of prospective stud-
ies that directly compare HSCT outcomes by age. Nonetheless, early
transplantation with an MSD is associated with reducedGVHD, lower
transplantation-related mortality, and higher OS. Transplantation at an
earlier age may also help preserve organ function. These benefits,
however, should be balanced against the potential for harm from
transplantation-related toxicity and mortality risks, which are never
nonexistent.
Other EtD criteria and considerations. The panel also valued
the likelihood of improved HRQOL and lifetime health-related cost
savings associated with successful HSCT at a younger age given
the known natural history of SCD.
The complete EtD framework for this question, including evidence
tables, is available at https://guidelines.ash.gradepro.org/profile/
eWAQORgWjrw.
Conclusions and research needs for this recommenda-
tion. The panel determined there is a low certainty in the evidence
for the net benefit of transplantation at a younger vs older age in
patients with SCD and an MSD. However, the panel believed that a
conditional recommendation was justified because of the ability to
use myeloablative regimens in younger patients, the preservation of
organ function prior to SCD-induced damage, and the likely cost sav-
ing. However, for those without an MSD, the recommendation is not
as strong, because the data are not sufficiently mature.
The panel identified the following areas of research that are needed:
(1) long-term comparative studies (SCT vs standard care) stratified
by complications and randomized by donor availability, such as the
recently reported39 DREPAGREFFE trial for children with abnormal
TCD and the ongoing BMT CTN 1503 trial, and (2) retrospective
studies comparing long-term effects depending on age at transplanta-
tion, such as gonadal function, fertility, and risk of malignancies.
Recommendation 8
In pediatric patients with SCD, an indication for BM transplantation,
and available cryopreserved matched sibling cord blood, should mye-
loablative BM transplantation be used vs myeloablative cord blood
transplantation?
Recommendation 8
The ASH guideline panel suggests the use of HLA-identical
sibling cord blood when available (and associated with an
adequate cord blood cell dose and good viability) over BM
(conditional recommendation, very low certainty in the evi-
dence about effects ⨁).
Specific background. Since 1988, UCB has been successfully
used as a source of stem cells for hematopoietic reconstitution in allo-
geneic HSCT. For patients with SCD, it is possible to propose and
organize the systematic cryopreservation of cord blood collection
from full siblings born after the patient with SCD. However, the bene-
fit/risk balance of using cord blood vs BM from anMSD for a child with
SCD and an indication of HSCT is not well understood.
Summary of the evidence. Studies were examined for the primary
outcomes of survival, graft failure/rejection, and acute and chronic
GVHD as well as secondary outcomes of interest from recommenda-
tions 1 to 3 where appropriate. There were 3 main studies that
reported retrospective comparisons of outcomes after UCB vs BM
transplantation in patients with SCD. The study by Locatelli et al92
evaluated individuals with all types of hemoglobinopathies and
included those with SCD (UCB, n530; BM, n5130). In a similar
study, Bernaudin et al91 reported the comparison of 30 UCB vs
195 BM transplantations in patients with SCD, and a recent report
by CIBMTR compared outcomes of 34 UCB vs 311 BM
transplantations.29
These studies reported a significantly longer median time to neutrophil
and platelet recovery after HSCT with a UCB donor when compared
with BM donor, but without a significantly increased risk of infections
or risk of nonengraftment. There were no deaths observed after UCB
transplantation, and there was a trend toward lower acute and chronic
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GVHD after UCB transplantation. OS and EFS were similar for all cell
sources.
Benefits. The benefit of cord blood is based primarily on the lower
risk of GVHD associated with using cord blood. However, the cer-
tainty in the evidence for effects was very low, because the patients
receiving UCB were usually younger than those receiving BM and
therefore at lower risk of GVHD regardless of cell source. Further-
more, these were retrospective studies that did not directly compare
other outcomes of interest (eg, organ function). Finally, OS is similar
in both groups. One additional potential benefit associated with using
UCB is the avoidance of donor risk/attrition, because cord blood col-
lection is without risk to the donor (ie, no requirement for general anes-
thesia or harvest procedure).
Harms and burdens. Harms associated with UCB transplantation
include the longer time to engraftment and therefore increased risk for
infection. This significantly longer recovery time for neutrophils and
platelets does increase the supportive care burden and the burden
of potential discomfort on the patient; however, this burden did not
translate into inferior overall outcomes. Additionally, it is difficult to bal-
ance the differences in efficacy with the risk of GVHD, because these
trials were not randomized. Despite the nonsignificance in
OS,14,91,92-96 it is important to note that no deaths were observed
after HSCT with UCB.
Rationale and key drivers for recommendation. The balance
between benefits vs harms probably favors UCB over BM for children
undergoing HSCT using an HLA-identical sibling based primarily on
decreased GVHD risk. However, the overall certainty in the evidence
is very low, because there are no RCTs to directly compare UCB with
BMHSCT, and additional information is needed to assess EFS. How-
ever, given the information available, the panel felt the current evidence
favors UCB over BM when there is a choice of stem cell product. It is
also important to discuss UCB HSCT with families of affected chil-
drenwho are considering having additional children.With this informa-
tion, families can opt to organize UCB cryopreservation in case the
new sibling is an HLA match.
Other EtD criteria and considerations. There are different
costs incurred between the different procedures, with cryopreserva-
tion and storage of UCB potentially having a higher cost than BM har-
vesting. Considering the successful use of UCB HSCT in patients
with SCD, in vitro fertilization combined with preimplantation genetic
diagnosis could increase access to MSD HSCT. However, feasibility
and high costs limit the usefulness of this therapeutic strategy. Further-
more, the ethical decision to have a child to serve as a UCBdonor also
warrants discussion if considering this option. Finally, there might also
be a benefit of combining a marrow harvest with UCB when the cord
blood cell dose is judged too small to support engraftment but could
still be used to reduce risk of GVHD, although this has not been
well studied.
The complete EtD framework for this question, including
evidence tables, is available at https://guidelines.ash.gradepro.org/
profile/yATgrmb9xE4.
Conclusions and research needs for this recommenda-
tion. The panel determined that there is very low certainty in the evi-
dence for a net benefit related to using UCB over BM. The panel can
only expect that with an increasing use of UCB HSCT, it will be pos-
sible to better determine the GVHD risk and OS/EFS compared with
BM HSCT. The panel can only conclude that for SCD children with
cryopreserved HLA-identical UCB, UCB HSCT offers a lower risk
of GVHD (provided a sufficient cell dose is available) and that UCB
may be combined with BM from the same donor with excellent results
whenUCBdose is limited.97,98 The panel identified the following addi-
tional areas of research that are needed: (1) studies comparing SCD-
related complications (eg, neurologic complications, pain crisis, and
ACS) and HRQOL after UCB vs BM transplantation, (2) studies eval-
uating the relative risks of opportunistic infection, hospital days, and
resource use after UCB vs BM transplantation, (3) studies comparing
the acceptability of UCB vs BM transplantation among the various
stakeholders (patients with SCD, parents, care providers, and others),
and (4) research regarding cord blood HSC expansion to enable both
improved recovery time for neutrophils and platelets and extension to
older/larger recipients.
Good practice statements for HSCT
1. Providers and health care centers that offer allogeneic HSCT to
patients with SCD should ensure that potential patients have
been seen and counseled by an SCD specialist in addition to a
specialist in HSCT to review all available treatment options.
2. Providers and health care centers that offer allogeneic HSCT to
patientswithSCDshouldbeadequately trained in thespecialized
care required by such patients, including supportive care, which
differs from that of other disease states.
3. Disease and transplantation-related outcomes should be moni-
tored in the short (,2 years) and long term (10-15 years) in all
patientsafterHSCTforengraftment,SCDsymptoms,organ func-
tion, GVHD, transplantation-related complications, secondary
malignancies, and (for patients undergoing alternative donor
HSCT) immune reconstitution.
4. Care providers should consider health literacy levels of patients
and their families when advising on HSCT.
5. Care providers should consider the burdens of the HSCT proce-
dure on patients and their families.
6. Shared decision making between patients and providers is sug-
gested to establish optimal HSCT plans.
Conclusions
The use of HSCT for SCD is evolving. The evidence for all recommen-
dations is of low or very low certainty because of the lack of RCTs for
HSCT in SCD, the lack of universal end points used in HSCT trials,
and the lack of direct comparative therapies. The conditional nature
of the recommendations for all questions results from the short dura-
tion of accumulated data and the reliance on evaluation of noncompar-
ative data. MSD HSCT should be considered for all individuals at risk
of neurologic injury or with recurrent vasoocclusive pain crises or a his-
tory of recurrent ACS. Furthermore, when feasible, the panel agreed
HSCT should be undertaken at the earliest age possible. However,
given the benefits and burdens of HSCT, the panel expressed strong
views that all patients (even those without an MSD) with severe com-
plications of SCD (indications for transplantation as above) should
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receive information about transplantation as an option. For adults with
SCD, undergoing HSCT with an MSD and nonmyeloablative therapy
is recommended. Overall, alternative donor HSCT and newer non-
myeloablative regimens should be undertaken in the context of a clin-
ical trial to better evaluate the efficacy and outcomes for future
recommendations.
Further research needed
These guidelines are clearly limited because of the low certainty in the
evidence. There are many reasons that evidence is lacking, and there
are several recommendations offered to improve upon the existing
recommendations.
Need for a clinical longitudinal registry
To fully realize the benefits vs harms assessment in HSCT for SCD, it
is first necessary to better characterize the current natural history of
SCD. Therefore, it is necessary to establish registries for both patients
who undergo transplantation and patients who do not. It is highly
important that a selected registry platform be validated, easy to
access, and highly accessible to all SCD centers. It is also imperative
that centers agree on which registry will be used and identify end
points that can be tracked longitudinally and compared between
those undergoing and not undergoing HSCT and are biologically rel-
evant. This is especially important because it is highly difficult to justify
comparative head-to-head studies that have transplantation as the
intervention compared with standard of care. Although these are
needed to optimally assess outcomes, such as long-term survival,
long-term morbidity, organ function, and secondary malignancy, these
are difficult to undertake. There are significant difficulties/challenges
involved with the implementation of RCTs comparing an already
proven curative approach with noncurative approaches, including
the ethical challenges posed by the withholding of a potentially cura-
tive therapy. As such, RCTs that properly address all of the gaps in our
knowledge are unlikely.
Increased access to care by SCD specialists for
individuals living with SCD
Optimal implementation of HSCT will need to consider access to an
SCD specialist, access to a transplantation center, compliance, and
social, financial, and logistic support. HSCT is likely cost effective.
Comparison of high-risk SCD adults who underwent HSCT using a
nonmyeloablative conditioning regimen vs those referred for HSCT
who did not proceed because of lack of an HLA-matched sibling
donor, denial by insurance, anti-HLA antibodies to the potential donor,
excessive RBC antibodies, or decision to decline further evaluation
suggested that allogeneic HSCT leads to improvements in health
care use and costs.99 An assessment of cost effectiveness in other
types of patients and types of transplantation with regard to long-
term outcomes remains necessary.
Furthermore, indications for HSCT must balance the increased risk of
toxicities in all transplantation settings to ensure that potential benefits
outweigh the risks and must be considered in the context of disease
burden with time and advancing patient age and the influence of sup-
portive care.
The ASH panel recommends the following: (1) at least 5 years of
follow-up and, if feasible, even longer-term follow-up for assessment
of transplantation-related complications and long-term efficacy and
monitoring of patient-reported outcomes, organ function, and
longevity (registry studies could be beneficial with regard to long-
term follow-up), (2) development of cohort studies for systematic
tracking, (3) uniform tracking methods between HSCT protocols,
and (4) outcome measures specific to HSCT and SCD. Research pri-
orities should include education regarding HSCT as a potential treat-
ment option for eligible patients and optimization of details of follow-up
parameters and duration. It is therefore important for patients with
SCD undergoing HSCT, especially those who undergo nonmyeloa-
blative and/or alternative donor HSCT, to be enrolled in clinical trials,
and it is important that funding be made available to support
this potentially curative intervention as well as to support long-term
follow-up.
Enhanced evaluation of newer disease-modifying
therapies and their impact on quality and length of
life for those living with SCD
There are new potentially disease-modifying medications (eg,
L-glutamine, crizanlizumab, and voxelotor) that have recently been
approved in the United States for SCD and ongoing development
of additional therapies both for new medical treatments and for
HSCT (eg, gene therapy). It is unclear how these newer therapies
will affect SCD outcomes, including organ complications, and if
broader access to a curative therapy will alter the trajectory of SCD
outcomes. It is possible that new recommendations will be needed
once long-term data are assembled on these newer agents.
Immense need for predictive biomarkers of mortality
in SCD
SCD is highly variable. Although several different blood and urine bio-
markers have been described in SCD, there are likely additional geno-
mic and environmental modifiers of disease that have not yet been
evaluated. Many of these biomarkers are organ specific (eg, microal-
buminuria or proliferative retinopathy), whereas others are more global
indications of SCD (eg, hemolysis, inflammation, and hypercoaguabil-
ity). Furthermore, many of the identified biomarkers are abnormal in the
steady state and become increasingly abnormal during acute vasooc-
clusive episodes, complicatingmeasurement. Despite this knowledge,
it is not clear that any current biomarkers provide specific prognostic
or clinical information beyond the acute period or can be prognosti-
cally used in children to suggest or predict mortality when they
become adults, preventing their use in HSCT. Thus, the identification
of prognostically validated biomarkers in additional to a longitudinal
clinical registry could greatly enhance the field of SCD treatment.
Updated data needed to evaluate newer alternative
donor transplantation regimens
Updated data are needed to assess newer regimens such as haploi-
dentical transplantation and add to this literature. These data must
include all of the relevant outcome data so that comparisons across
donor types can be performed. Additionally, these data must be col-
lected across newly evolving curative therapy approaches, such as
those involving gene disruption for fetal hemoglobin reactivation or
gene correction using genome editing and addition tools.
What are others saying, and what is new in
this ASH guideline?
To date, the only other official guideline on the use of HSCT in SCD
was developed by the European Blood and Marrow Transplantation
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Inborn Error Working Party and the Pediatric Disease Working Party
and published in 2014.100 The committee panel included 20 mem-
bers with clinical and scientific expertise in HSCT and/or medical
management of SCD. That guideline also used the GRADE approach
as above. Patient stakeholders were not included in the working
groups. They recommended that children with symptomatic SCD
who have an HLA-matched sibling donor undergo SCT, consistent
with recommendations 1 and 2 from this panel.14 In contrast, they
are more liberal in their recommendations for unrelated donor
HSCT, stating more strongly that a transplant from an unrelated donor
should be considered if a patient has at least 1 major organ-related
complication or recurrent pain episodes. They do suggest that unre-
lated donor transplantation only be undertaken as a controlled trial
in an experienced center as per the recommendations in this guideline.
This panel did not fully endorse this recommendation, because there
are no long-term data to support HSCT for certain organ complica-
tions, such as renal nephropathy and lung disease. For patients with
neurologic indication or recurrent pain episodes or ACS, their recom-
mendations parallel those in this document.
Limitations of this guideline
The limitations of this guideline are inherent to the low or very low cer-
tainty in the evidence we identified for many of the questions. In these
cases, the panelists judged that patients who choose the suggested
intervention would likely be better off than those who do not. As is
clearly written, our recommendations are not intended for standard
of care but rather for people seeking these specific therapies. Please
note that the panel suggested multiple areas of important future
research and emphasized the importance of shared decision making.
The recommendations are consistent with the GRADE approach,
which allows for recommendations even in situations of low certainty
in the evidence. It could be argued that recommendations and guide-
lines such as these are often more important when the certainty in evi-
dence is very low, compared with when there is high certainty. The
panel made these recommendations with the best judgment of the evi-
dence (although scant), information about the disease, and relevant
contextual factors.
Revision or adaptation of the guideline
Plans for updating the guideline
After publication of this guideline, ASH will maintain it through surveil-
lance for newevidence, ongoing reviewby experts, and regular revisions.
Updating or adapting recommendations locally
Adaptation of this guideline will be necessary in many circumstances.
These adaptations should be based on the associated EtD
frameworks.101
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